Table 2.
Comparison of baseline characteristics of nontrial patients with participants enrolled in select group 2 and group 3 pulmonary hypertension randomized clinical trials
| Cohort Characteristic | Nontrial Cohort | Trial cohort* | Group 2 PH Trials |
Group 3 PH Trials |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bonderman (11) | Bermejo (1) | Kaluski (12) | Vachiéry (13) | Hoendermis (14) | Nathan (2) | Goudie (15) | Raghu (16) | ||||
| n | 136,670 | 938 | 201 | 200 | 87 | 63 |
52 | 147 | 120 | 68 | |
| Age, yr, mean (SD) | 76.8 (9.5) | 67.1† | 58.1‡ | 70.0‡ | 69.5 (9.4) | 70.0‡ |
74.0 (9.9) | 68.5 (8.0) | 69.0 (7.6) | 68.0 (6.1) | |
| Female sex | 2.5% | 42.3% | 14.4% | 77.0% | 28.7% | 65.1% |
71.2% | 35.4% | 31.7% | 30.9% | |
| Race/ethnicity | |
||||||||||
| White | 85.3% | 95.1% | — | 100% | 98.9% | — |
96.2% | 85.7% | 100% | 86.8% | |
| Black | 9.4% | 1.2% | — | 0% | 1.1%§ | — |
3.8%§ | 2.7% | 0% | 1.5% | |
| Hispanic | 1.9% | 0.9% | — | 0% | — | — |
— | 3.4% | 0% | 0% | |
| Comorbid conditions | |
||||||||||
| Diabetes | 49.7% | 29.4% | 43.3% | 29.0% | 36.8% | 42.9% |
34.6% | 29.9% | 8.3% | — | |
| Smoking | 41.8% | 34.6% | — | 6.5% | — | — |
— | 4.1% | 100% | 67.6% | |
| Hypertension | 92.9% | 61.7% | — | 64.0% | 66.7% | 90.5% |
90.4% | 55.8% | 34.2% | — | |
| Hyperlipidemia | 81.7% | 33.7% | — | 42.5% | 54.0% | 7.9% |
51.9% | 14.3% | — | — | |
| Chronic kidney disease | 40.1% | 6.6% | 0%ǁ | 0%ǁ | — | 39.7% |
— | 8.2% | 9.2% | — | |
| Cerebrovascular disease | 17.4% | 8.5% | — | — | — | — |
15.4% | 6.8% | 7.5% | — | |
| Heart disease | 67.9% | 20.7% | 0%ǁ | 13.5% | 72.4% | — |
32.7% | 34.7% | 7.5% | — | |
| Arrhythmia | 63.1% | 34.1% | 12.9% | 77.0% | 20.7% | 73.0% | 61.5% | 10.2% | 5.0% | — | |
Definition of abbreviations: PH = pulmonary hypertension; SD = standard deviation.
Data are presented as percentages unless otherwise noted; data not available from authors is designated as —.
*
Pooled estimate calculated on the basis of available data.
†
Pooled SD unable to be calculated because SD was not provided for all studies.
‡
SD not provided.
§
Maximum value possible based on prevalence of other races.
ǁ
Assumed on the basis of trial exclusion criteria.